Company intelligence / Profile preview

Zhongshan Medical Novishen New Drug R & D Co., Ltd.

Zhongshan City, Guangdong Sheng / Province, Chinazs.gov.cn ↗

Ownership: Private
Development stage: Preclinical

Overview

Zhongshan Medical Novishen New Drug R & D Co., Ltd. is a private Chinese biotech company focused on developing small molecule drugs for oncology. Its lead asset, FC084CSA, is an AXL inhibitor currently in Phase 1/2 clinical trials for advanced malignant solid tumors. The company has at least one IND approval and is actively recruiting for clinical studies as of early 2025

Therapeutic areas: Oncology
Modalities: Small molecules (AXL inhibitor)
Industry: Biotech

Drug pipeline

1 asset

FC084CSA

Partnerships

FindCure Biosciences (ZhongShan) Co., Ltd. appears to be a key partner or affiliate involved with the development of FC084CSA and related oncology programs

Beyond the preview

Go deeper on Zhongshan Medical Novishen New Drug R & D Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhongshan Medical Novishen New Drug R & D Co., Ltd..

Explore the full profile